SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending after its strong earnings report revealed robust demand for its AI platform and optimistic forward guidance, sparking widespread bullish excitement for significant upside, though some investors continue to debate its elevated valuation.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending ahead of its highly anticipated earnings report, with investors keenly focused on a projected revenue surge and potential impact from Elon Musk's xAI merging with SpaceX. The community is sharply divided between expectations of a massive short squeeze fueled by undervaluation and critical AI infrastructure, and concerns over potential margin pressures and past earnings disappointments.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending intensely ahead of its expected earnings report, with community sentiment sharply divided between those who view the fintech giant as a deeply undervalued cash-generating machine poised for a turnaround, and others convinced it's a stagnant company facing relentless competition and further declines. Investors are eagerly awaiting clarity on management's strategy to combat perceived market share loss and capitalize on new growth initiatives amidst a prevailing bearish narrative despite low valuation metrics.

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics Inc

Atossa Therapeutics (ATOS) is heavily discussed following its approved 1-for-15 reverse stock split, effective February 2, 2026, which the community largely views as a detrimental move signaling future dilution and concerns over CEO Steven Quay's management.

Tidal Trust II - Defiance Daily Target 2x Short PLTR ETF

Defiance Daily Target 2x Short PLTR ETF

PLTZ, a 2x short ETF for Palantir (PLTR), is trending as traders anticipate a significant pullback in PLTR, driven by widespread community concerns over its extreme valuation, high P/E ratio, and ongoing fears of a broader "AI bubble." The ETF is actively discussed as a strategic way to capitalize on perceived overextension in PLTR, especially amid reports of insider selling and increasing competition.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Teva Pharmaceutical Industries is gaining attention after recent strong earnings, driven by robust branded drug sales and pipeline progress, including expanded FDA approvals for Uzedy. The community is actively discussing the company's "Pivot to Growth" strategy and perceived undervaluation, alongside a class-action lawsuit concerning alleged anti-competitive practices.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is trending following a Q3 EPS miss attributed to tariff impacts on device margins, despite solid revenue growth and raised full-year guidance. The community is actively debating its high valuation and recent price drop against the company's market dominance, strategic AI-focused acquisitions, and potential for major government contracts, particularly the anticipated ICE bodycam mandate.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics is highly active following a significant equity offering, viewed by some as strategic capital infusion from institutional investors and by others as dilution, occurring simultaneously with competitor Sanofi deprioritizing a rival therapy. The community is buzzing with speculation about a potential buyout and the company's promising radiopharmaceutical pipeline, driving notable volume and price target discussions amidst its role in the growing precision oncology sector.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is surging on intense speculation that Ryan Cohen is preparing a "monumental" acquisition with the company's substantial cash reserves, fueling community excitement for a potential short squeeze and a return of "Roaring Kitty" activity.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is trending following its latest earnings report, where robust overall performance was overshadowed by soft near-term revenue guidance, leading to a significant stock decline. The community is actively debating whether this represents an overreaction and a buying opportunity given the company's strong cash position and strategic role in the AI memory market, or if it signals valid execution risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 743,709 shares, an...

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50-Day Moving Average - Here's What Happened

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 50 Day Moving Average - Time to Sell...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock...

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Above Fifty Day Moving Average - What's Next?

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Above Fifty Day Moving Average - Here's What Happened...

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 Karyopharm Announces Preliminary Unaudited 2025...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm...

Nuclear Stocks To Consider - December 12th

Oklo, NuScale Power, Centrus Energy, BWX Technologies, Nano Nuclear Energy, Lightbridge, and Karyopharm Therapeutics are the seven Nuclear stocks to watch today, according to MarketBeat's stock...

Top Nuclear Stocks To Consider - December 9th

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving Average - Here's What Happened

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above Fifty Day Moving Average - Here's Why...

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMD earnings on Tuesday?

KPTI
Karyopharm Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KPTI News

KPTIKaryopharm Therapeutics Inc